InSysBio to start the operation of new Headquarters and new branch office

NEWS
Press-Release
November 9, 2022

November 9, 2022

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the start of operation of Headquarters in Edinburgh, the United Kingdom. At the same time, the new branch office has been founded in LimassolCyprus and part of InSysBio team has relocated there, thus, expanding the company’s presence. Previously InSysBio has been operating in Edinburgh, UK and Moscow, Russia.

InSysBio continues the development of its QSP services and QSP tools infrastructure according to its mission, vision and values. We hope this step will assist in providing QSP modeling to world pharma, contributing our expertise to global QSP community and creating favorable atmosphere for self-development of researchers.

Oleg Demin, one of the co-founders of InSysBio, comments on the significance of this step, "I am pleased to share that we have established the new Headquarters in the United Kingdom, and relocated part of InSysBio team to Cyprus. I am sure that soon Cyprus will become one of the countries distinguished on the “QSP community map”. We will do all our best to achieve this goal”.

Innovative approach applied by InSysBio has already become part of the drug development process implemented by our strategic partners and is under constant enhancement. The range of tools of InSysBio's QSP software infrastructure embraces Heta compiler, HetaSimulator.jl, Immune Response Template (IRT), CYTOCON DB, fIVE DB, DBSolveOptimum, SbmlViewer, LikelihoodProfiler. The implementation of QSP tools allows to simplify model development process. Moreover, InSysBio team provides educational assistance to academic entities.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Edinburgh, UK (INSYSBIO UK LIMITED), Moscow, Russia (INSYSBIO LLC) and Cyprus (INSYSBIO CY Ltd). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

March 2022
MoTuWeThFrSaSu
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
1. 17 Mar 2022 14:17 InSysBio to present posters at AACR Annual Meeting 2022 InSysBio team is going to present its posters in frames of American Association for Cancer Research (AACR) Annual Meeting 2022 which is to be held April 8-13, New Orleans, Louisiana. The abstracts have been published on AACR website and E-Posters are going to be presented if frames of Poster Sessions
18
19
20
21
22
23
24
25
26
27
28
29
1. 29 Mar 2022 13:44 InSysBio to take part in QSPC2022 InSysBio announces its participation in Quantitative Systems Pharmacology Conference 2022 (QSPC2022) which is to be held on April 20-22, 2022, Leiden, The Netherlands. InSysBio team is going to present its QSP tools at the Booth and 15 posters in frames of the Conference
30
31
   
Upcoming Events
Tags
Latest News
15.05
15th InSysBio’s Annual Internal Scientific Meeting
09.04
InSysBio to release a new version of LikelihoodProfiler.jl
31.03
InSysBio to launch Immune Response Template version 3.7.0 for QSP modeling
19.03
InSysBio announces its collaboration with discoveric bio alpha
19.02
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology